Biopharmaceutical News and Research

RSS

Enterprise Therapeutics doses first person with cystic fibrosis in Phase 2 trial for novel therapy ETD001

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of those suffering from respiratory disease, today announced dosing of the first person with cystic fibrosis (pwCF) in its Phase 2a trial of ETD001.

24 Jul 2024

Lario Therapeutics awarded $6M Grant from The Michael J. Fox Foundation for Parkinson’s Research

Award supports preclinical research of Lario’s CaV2.3 calcium channel inhibitors as a novel disease-modifying approach for treatment of Parkinson's disease.

23 Jul 2024

Almirall's Ebglyss recommended by NICE for NHS atopic dermatitis patients

Almirall S.A., a global biopharmaceutical company dedicated to medical dermatology, announced today that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe Atopic Dermatitis in the NHS England.

13 Jul 2024

Click-like chemistry enables rapid development of LNPs for enhanced mRNA delivery

Imagine a scenario where a skilled hacker must upload critical software to update a central server and thwart a potentially lethal virus from wreaking havoc across a vast computer network.

10 Jul 2024

Agreement to explore Optimer vehicles for targeted delivery of siRNA

New collaboration will evaluate Aptamer’s fibrotic liver delivery vehicles with siRNA.

From Aptamer Group 9 Jul 2024

ELRIG UK and The Protein Society Partner to advance protein sciences in drug discovery

Partners to host joint conference on ‘Protein Sciences in Drug Discovery’ in Cambridge, UK from 18–19 November 2024.

From ELRIG (UK) Ltd. 26 Jun 2024

UT Health Science Center awarded $1.58M grant to study cancer disparities among Black women

A $1.58 million grant will support work by a health communication scholar at the University of Tennessee (UT) Health Science Center's College of Nursing and a medical oncologist at West Cancer Center and Research Institute (WCCRI) to identify sociocultural and structural factors that are root causes of cancer health disparities for Black women in the Mid-South.

20 Jun 2024

WEHI spinout aims to revolutionize the development of cancer drugs

Australia has cemented its role in becoming a major player in the next generation of medicines with the launch of Ternarx – a globally competitive biotechnology company dedicated to finding new treatments for hard-to-treat cancers.

20 Jun 2024

Gyros Protein Technologies introduces Gyrolab Generic Anti-AAV Kit to support gene therapy development

Ready-to-use kit enables detection of binding antibodies against AAV vectors without the need for serotype-specific assays.

From Gyros Protein Technologies AB 17 Jun 2024

Enterprise Therapeutics appoints Dr Renu Gupta as Chief Medical Officer and Dr Janet Hammond as Non-Executive Director

Appointments bring additional respiratory and late clinical-stage drug development experience as Company commences Phase 2a clinical trial of its lead asset.

From Enterprise Therapeutics Ltd 17 Jun 2024

Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced the publication of a peer reviewed study in the Journal of Cystic Fibrosis1.

12 Jun 2024

InDevR and Sino Biological team up to deliver multiplexed analytical solutions for mRNA vaccine and cell & gene therapy

InDevR, Inc., a leader in analytical solutions for vaccine in-process and quality control testing, and Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext specializing in biological research reagents and related technical contract research services, today announced a new partnership to speed development of multiplexed assays for a broad range of vaccine, mRNA therapies and cell and gene therapy applications.

From Sino Biological Inc. 7 Jun 2024

Novel small molecule oral antiviral could be a game-changer in the fight against future pandemics

Obeldesivir (GS-5245), a novel investigational small molecule oral antiviral, represents a new tool in the ongoing effort to prepare for future pandemics.

4 Jun 2024

DefiniGEN and Atelerix collaborate to ship in vitro cell models internationally without the need for freezing or cryopreservation

DefiniGEN Ltd., and Atelerix Ltd., today announced they have successfully shipped in vitro liver models from the UK to a top tier pharma customer in the US. The agreement between the companies combines DefiniGEN’s mechanistically relevant iPSC hepatocytes (Opti-Heps) with Atelerix's hydrogel preservation technology, which prevents loss of function and enables even sensitive samples to remain stable at ambient temperatures for up to two weeks.

From Defini Gen 3 Jun 2024

UMSOM receives $3.96 million grant for maternal vaccine against neonatal sepsis

University of Maryland School of Medicine (UMSOM) researchers at the Center for Vaccine Development and Global Health (CVD) have been awarded $3.96 million to develop a maternal vaccine that prevents sepsis caused by Klebsiella pneumoniae in newborns and infants.

23 May 2024

Refeyn strengthens capability with new US Headquarters in Boston area

Refeyn, the pioneer of mass photometry technology, is continuing to strengthen the deployment of its unique bioanalytical tools with the planned Grand Opening of its new US Headquarters and Customer Interaction Center, in conjunction with the third annual Mass Photometry Summit 2024. Following the summit, highlighting the very latest advances in mass photometry, to be held in the Boston area on May 22, Refeyn will officially open its new 10,000 sq. ft. HQ in the heart of Waltham’s Biotech Hub in Greater Boston, Massachusetts, on May 23.

From Refeyn 23 May 2024

CYTENA unveils revolutionary C.WASH PLUS: The future of microplate washing and dispensing

CYTENA, a BICO company, proudly announces the launch of C.WASH PLUS, a cutting-edge microplate washer and dispenser. Engineered for high throughput and automation, the C.WASH PLUS delivers unparalleled consistency and precise dispensing for immune and cell-based assays.

From CYTENA GmbH 22 May 2024

PhoreMost introduces GlueSEEKER platform for discovery of molecular glue degraders

PhoreMost Ltd., a leading UK biopharmaceutical company unlocking the next generation of drug targets, today announced the introduction of GlueSEEKER™.

From PhoreMost 22 May 2024

RedShiftBio launches Aurora TX: Revolutionizing RNA and protein analysis with ultra-sensitive microfluidic modulation spectroscopy and thermal ramping capability

RedShiftBio, a leader in innovative biophysical characterization and bioprocess analytical solutions, proudly announces the launch of Aurora TX at The Protein & Antibody Engineering Summit (PEGS), kicking off on May 13, 2024, in Boston, MA. Aurora TX is the company's latest, most advanced instrument featuring ground-breaking MMS technology, and sets a new standard in biomolecular analysis by providing ultra-sensitive, ultra-precise measurements of biomolecule structure and stability, now enhanced with the addition of thermal ramping capability.

From RedShiftBio 16 May 2024

ArgusEye closes €2.8 million funding to accelerate bioprocessing

ArgusEye, a provider of innovative sensor solutions for real-time monitoring of biological systems, today announced the close of its funding, raising €2.8 million EUR (~£2.4 million GBP) bringing the total raised by the Company to €3.45 million EUR (~£3 million GPB).

From ArgusEye AB 13 May 2024